
Gung ho: Alnylam lands historic FDA OK on patisiran, revving up the first global rollout for an RNAi breakthrough
“A lot of people think it’s winter out there for RNAi. But I think it’s springtime.” — Alnylam CEO John Maraganore, NYT, February 7, 2011.
Marketing season has officially arrived for RNAi, just two decades in the making.
On Friday, the FDA approved Alnylam’s patisiran, offering a historic green light for a drug that is breaking the waves in therapeutic innovation.
Over the past 16 years since Alnylam $ALNY was founded, John Maraganore has seen everything when it comes to RNAi. He benefited from the early promise and rush of Big Pharmas looking to get a foot in the door, lured in by tech that promised to switch genes on and off.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.